101 related articles for article (PubMed ID: 28402273)
21. Relationship between circulating interleukin-10 (IL-10) with interleukin-6 (IL-6) type cytokines (IL-6, interleukin-11 (IL-11), oncostatin M (OSM)) and soluble interleukin-6 (IL-6) receptor (sIL-6R) in patients with multiple myeloma.
Urbańska-Ryś H; Wiersbowska A; Stepień H; Robak T
Eur Cytokine Netw; 2000 Sep; 11(3):443-51. PubMed ID: 11022130
[TBL] [Abstract][Full Text] [Related]
22. [GRP78 expression in gastric cancer and its clinical significance].
Yang L; Yang SY; Ji JM; Cao YF; Ji CF; Ji JF; Xu WW; Wang JH
Zhonghua Zhong Liu Za Zhi; 2013 Nov; 35(11):837-42. PubMed ID: 24447482
[TBL] [Abstract][Full Text] [Related]
23. Serum interleukin-10 levels in patients with advanced gastrointestinal malignancies.
De Vita F; Orditura M; Galizia G; Romano C; Infusino S; Auriemma A; Lieto E; Catalano G
Cancer; 1999 Nov; 86(10):1936-43. PubMed ID: 10570416
[TBL] [Abstract][Full Text] [Related]
24. Characterization of serum interleukin-15 in healthy volunteers and patients with early arthritis to assess its potential use as a biomarker.
Lamana A; Ortiz AM; Alvaro-Gracia JM; Díaz-Sánchez B; Novalbos J; García-Vicuña R; González-Alvaro I
Eur Cytokine Netw; 2010 Sep; 21(3):186-94. PubMed ID: 20736143
[TBL] [Abstract][Full Text] [Related]
25. Serum interleukin-6 level but not genotype predicts survival after resection in stages II and III gastric carcinoma.
Liao WC; Lin JT; Wu CY; Huang SP; Lin MT; Wu AS; Huang YJ; Wu MS
Clin Cancer Res; 2008 Jan; 14(2):428-34. PubMed ID: 18198221
[TBL] [Abstract][Full Text] [Related]
26. Randomized, Double-Blind Phase II Trial With Prospective Classification by ATM Protein Level to Evaluate the Efficacy and Tolerability of Olaparib Plus Paclitaxel in Patients With Recurrent or Metastatic Gastric Cancer.
Bang YJ; Im SA; Lee KW; Cho JY; Song EK; Lee KH; Kim YH; Park JO; Chun HG; Zang DY; Fielding A; Rowbottom J; Hodgson D; O'Connor MJ; Yin X; Kim WH
J Clin Oncol; 2015 Nov; 33(33):3858-65. PubMed ID: 26282658
[TBL] [Abstract][Full Text] [Related]
27. CA125 level as a predictor of progression-free survival and overall survival in ovarian cancer patients with surgically defined disease status prior to the initiation of intraperitoneal consolidation therapy.
Juretzka MM; Barakat RR; Chi DS; Iasonos A; Dupont J; Abu-Rustum NR; Poynor EA; Aghajanian C; Spriggs D; Hensley ML; Sabbatini P
Gynecol Oncol; 2007 Jan; 104(1):176-80. PubMed ID: 16996584
[TBL] [Abstract][Full Text] [Related]
28. Feasibility of Modified FOLFOX in Elderly Patients Aged ≥80 Years with Metastatic Gastric Cancer or Colorectal Cancer.
Lim KH; Lee HY; Park SB; Song SY
Oncology; 2017; 93(2):115-121. PubMed ID: 28445892
[TBL] [Abstract][Full Text] [Related]
29. Depth of response predicts the clinical outcome of advanced HER2-positive gastric cancer to trastuzumab-based first-line chemotherapy.
Kadowaki S; Masuishi T; Eto T; Narita Y; Taniguchi H; Ura T; Ando M; Tajika M; Niwa Y; Yatabe Y; Muro K
Cancer Chemother Pharmacol; 2017 Oct; 80(4):807-813. PubMed ID: 28821938
[TBL] [Abstract][Full Text] [Related]
30. Second-line chemotherapy with biweekly paclitaxel after failure of fluoropyrimidine-based treatment in patients with advanced or recurrent gastric cancer: a report from the gastrointestinal oncology group of the Tokyo cooperative oncology group, TCOG GC-0501 trial.
Koizumi W; Akiya T; Sato A; Yamaguchi K; Sakuyama T; Nakayama N; Tanabe S; Higuchi K; Sasaki T; Sekikawa T;
Jpn J Clin Oncol; 2009 Nov; 39(11):713-9. PubMed ID: 19812061
[TBL] [Abstract][Full Text] [Related]
31. Rilotumumab in combination with epirubicin, cisplatin, and capecitabine as first-line treatment for gastric or oesophagogastric junction adenocarcinoma: an open-label, dose de-escalation phase 1b study and a double-blind, randomised phase 2 study.
Iveson T; Donehower RC; Davidenko I; Tjulandin S; Deptala A; Harrison M; Nirni S; Lakshmaiah K; Thomas A; Jiang Y; Zhu M; Tang R; Anderson A; Dubey S; Oliner KS; Loh E
Lancet Oncol; 2014 Aug; 15(9):1007-18. PubMed ID: 24965569
[TBL] [Abstract][Full Text] [Related]
32. Serum levels of soluble programmed cell death ligand 1 as a prognostic factor on the first-line treatment of metastatic or recurrent gastric cancer.
Takahashi N; Iwasa S; Sasaki Y; Shoji H; Honma Y; Takashima A; Okita NT; Kato K; Hamaguchi T; Yamada Y
J Cancer Res Clin Oncol; 2016 Aug; 142(8):1727-38. PubMed ID: 27256004
[TBL] [Abstract][Full Text] [Related]
33. Capecitabine and cisplatin with or without cetuximab for patients with previously untreated advanced gastric cancer (EXPAND): a randomised, open-label phase 3 trial.
Lordick F; Kang YK; Chung HC; Salman P; Oh SC; Bodoky G; Kurteva G; Volovat C; Moiseyenko VM; Gorbunova V; Park JO; Sawaki A; Celik I; Götte H; Melezínková H; Moehler M;
Lancet Oncol; 2013 May; 14(6):490-9. PubMed ID: 23594786
[TBL] [Abstract][Full Text] [Related]
34. [Comparison of Response to Chemotherapy between Ovarian and Extraovarian Metastasis of Gastric Cancer].
Ishimoto U; Nakamura S; Sasaki Y; Takahashi N; Iwasa S; Honma Y; Okita N; Takashima A; Kato K; Hamaguchi T; Boku N
Gan To Kagaku Ryoho; 2017 Mar; 44(3):233-237. PubMed ID: 28292993
[TBL] [Abstract][Full Text] [Related]
35. Predictive factors for the efficacy of cetuximab plus chemotherapy as salvage therapy in metastatic gastric cancer patients.
Park SR; Kook MC; Choi IJ; Kim CG; Lee JY; Cho SJ; Kim YW; Ryu KW; Lee JH; Lee JS; Park YI; Kim NK
Cancer Chemother Pharmacol; 2010 Feb; 65(3):579-87. PubMed ID: 19629485
[TBL] [Abstract][Full Text] [Related]
36. Plasma miR-122 and miR-192 as potential novel biomarkers for the early detection of distant metastasis of gastric cancer.
Chen Q; Ge X; Zhang Y; Xia H; Yuan D; Tang Q; Chen L; Pang X; Leng W; Bi F
Oncol Rep; 2014 Apr; 31(4):1863-70. PubMed ID: 24481716
[TBL] [Abstract][Full Text] [Related]
37. Relationship between 6- and 9-month progression-free survival and overall survival in patients with metastatic urothelial cancer treated with first-line cisplatin-based chemotherapy.
Galsky MD; Krege S; Lin CC; Hahn N; Ecke T; Moshier E; Sonpavde G; Godbold J; Oh WK; Bamias A
Cancer; 2013 Aug; 119(16):3020-6. PubMed ID: 23720197
[TBL] [Abstract][Full Text] [Related]
38. Apatinib for chemotherapy-refractory advanced metastatic gastric cancer: results from a randomized, placebo-controlled, parallel-arm, phase II trial.
Li J; Qin S; Xu J; Guo W; Xiong J; Bai Y; Sun G; Yang Y; Wang L; Xu N; Cheng Y; Wang Z; Zheng L; Tao M; Zhu X; Ji D; Liu X; Yu H
J Clin Oncol; 2013 Sep; 31(26):3219-25. PubMed ID: 23918952
[TBL] [Abstract][Full Text] [Related]
39. Cytokine and cytokine receptor serum levels in adult bone sarcoma patients: correlations with local tumor extent and prognosis.
Rutkowski P; Kamińska J; Kowalska M; Ruka W; Steffen J
J Surg Oncol; 2003 Nov; 84(3):151-9. PubMed ID: 14598359
[TBL] [Abstract][Full Text] [Related]
40. Neoadjuvant chemoradiotherapy followed by D2 gastrectomy in locally advanced gastric cancer.
Kim MS; Lim JS; Hyung WJ; Lee YC; Rha SY; Keum KC; Koom WS
World J Gastroenterol; 2015 Mar; 21(9):2711-8. PubMed ID: 25759540
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
